Search

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Prioritizing mental health and well-being today and every day

Prioritizing Mental Health and Well-being Today and Everyday

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

Achieving Health Equity: The Importance of Patient Input at Every Phase of Care

Learn more about how our BI Diversity and Inclusion Patient Council illuminates the impact of health inequities & how we can work together to be upstanders.

New consortium EUbOPEN will provide tools to unlock disease biolog

Advocating for More Patient-Centered Mental Health Care

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Prioritizing mental health and well-being today and every day

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

Achieving Health Equity: The Importance of Patient Input at Every Phase of Care

New consortium EUbOPEN will provide tools to unlock disease biolog

Advocating for More Patient-Centered Mental Health Care

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals